For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

< Back to Agenda
Reimagining Patient Access
Friday, May 31, 2024 03:45 PM - 04:45 PM  
Room 217-219
Concurrent Session
Chair
  • Mark Flower, BSc, Cryoport Systems, United States
Speakers
  • Peter Holman, BC, MS, Arsenal Biosciences, United States 
  • Antinea Chair, BSc, Cellares, United States
  • Julie Kanter, MD, University of Alabama at Birmingham, United States
  • Matthew L. Plaud, MSM, Chief Operations Officer, Cryoport Systems, United States
What impact will cutting-edge supply chain solutions, distributed networks, and emerging manufacturing technologies have on both centralized and decentralized manufacturing models? How should we adapt to accommodate the needs of evolving and expanding patient populations?

Session Objectives
  • Planning for growth and scalability today and reviewing
    lessons learned from the cell and gene therapy
    developers’ perspective
  • Impact of new patient populations on cell collections,
    manufacturing, and clinical settings
  • Logistics and supply chain approaches 
Mark Flower
VP Business Development
 Cryoport, Inc.
 Chair
Peter Holman
VP Quality
 Arsenal Biosciences
 Panelist
Antinea Chair
VP, Technical Operations
 Cellares
 Panelist
Julie Kanter
Director, Adult Sickle Cell Disease Program
 The University of Alabama at Birmingham
 Panelist
Matthew Plaud
COO
 IntegriCell - Cryoport Systems
 Panelist
< Back to Agenda